Account
Inquiry
Our semaglutide vial is produced under strict GMP guidelines, ensuring high purity and consistency for research applications. The product is supplied as a lyophilized powder in vials, with options for 5mg, 10mg, and 20mg strengths. Each semaglutide vial is designed to maintain stability and efficacy, making it suitable for laboratory and clinical research settings.
Tirzepatide, which shares a similar sequence with semaglutide, features a PEG-modified lys side chain that enhances water solubility. This modification is crucial for the polypeptide's functionality. Tirzepatide acts as a dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, currently in clinical development for type 2 diabetes treatment. It has shown promise in promoting weight loss in overweight individuals, with phase 3 trials ongoing.
In the SURMOUNT-1 clinical trial, tirzepatide demonstrated significant weight loss results: 15% average reduction with the 5mg dose, 19.5% with 10mg, and 20.9% with 15mg over 72 weeks. This once-weekly administration offers convenience and effectiveness, representing an innovative approach in metabolic disorder therapeutics.
Our semaglutide vial is ideal for researchers focusing on obesity, diabetes, and related metabolic conditions. It is provided in a sterile, lyophilized form to ensure easy reconstitution and application in various experimental setups. Each batch undergoes rigorous quality control to meet pharmacy grade standards.
This product is strictly for research use and not intended for personal consumption. Proper storage at 2-8 degrees Celsius after opening is recommended to preserve integrity and performance.
